Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
9.72
+0.20 (2.10%)
At close: Oct 20, 2025, 4:00 PM EDT
9.77
+0.05 (0.51%)
After-hours: Oct 20, 2025, 7:34 PM EDT
Arvinas Revenue
Arvinas had revenue of $22.40M in the quarter ending June 30, 2025, a decrease of -70.72%. This brings the company's revenue in the last twelve months to $372.80M, up 299.57% year-over-year. In the year 2024, Arvinas had annual revenue of $263.40M with 235.54% growth.
Revenue (ttm)
$372.80M
Revenue Growth
+299.57%
P/S Ratio
1.89
Revenue / Employee
$866,977
Employees
430
Market Cap
713.62M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ARVN News
- 18 hours ago - Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy - GlobeNewsWire
- 7 days ago - Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress - GlobeNewsWire
- 15 days ago - Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire
- 19 days ago - Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire
- 4 weeks ago - Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party - Reuters
- 4 weeks ago - Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation - GlobeNewsWire
- 5 weeks ago - Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 7 weeks ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire